Thrombophilia is the term used to describe an hereditary or acquired predisposition to thromboembolism (the formation of a venous clot), which manifests itself as either deep vein thrombosis (DVT) or pulmonary embolism (PE). The presence of thrombophilia can be tested and many people with venous thrombosis or pulmonary embolism nowadays have their blood tested for a deficiency in natural anticoagulants such as antithrombin, protein C, or protein S. However, the benefits of these costly tests are uncertain. The most important benefit would be a reduction in the risk of developing a new venous clot by taking preventative measures. To date no high quality trials have assessed this issue.
Vollständige Zusammenfassung lesen
Tests for thrombophilia are being performed on a large scale in people after venous thromboembolism (VTE) even though the benefits of testing are still subject to debate. The most important benefit would be a reduction in the risk of recurrent VTE due to the use of additional prophylactic measures. This is an update of a review first published in 2009.
Zielsetzungen
The objective of this review was to assess the benefit of testing for thrombophilia after VTE in terms of risk reduction of recurrent VTE.
Suchstrategie
For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 21 2012) and CENTRAL (2012, Issue 5). The authors searched MEDLINE and EMBASE.
Auswahlkriterien
Randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that compared the rate of recurrent VTE in participants with VTE who were tested for thrombophilia with the rate in participants with VTE who were not tested were eligible.
Datensammlung und ‐analyse
We planned to extract data from identified studies using data extraction forms.
Hauptergebnisse
No studies were included because no RCTs or CCTs could be identified.
Schlussfolgerungen der Autoren
There are currently no randomized controlled trials or controlled clinical trials that have assessed the benefit(s) of testing for thrombophilia on the risk of recurrent VTE.
